menu ☰
menu ˟

OBI Pharma receives FDA orphan drug designation for HCC therapy

10 Jul 2018
OBI Pharma received FDA orphan drug designation for OBI-3424 for the treatment of hepatocellular carcinoma, according to a press release.OBI-3424 is a first-in-class DNA alkylating cancer therapeutic designed to target aldo-keto reductase 1C3 overexp...

Click here to view the full article which appeared in Hepatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.